The FDA’s Peptide Vote Is Two Weeks Out

The comment window that actually reaches the advisory panel closed this week, which turns the next fourteen days into the most consequential stretch the research-peptide market has faced in years.

The seven-peptide docket is now locked. On July 9 the written-comment deadline passed for the FDA’s Pharmacy Compounding Advisory Committee (PCAC), so whatever the panel reads before its July 23 and 24 meeting is set. The committee weighs BPC-157, KPV, TB-500, and MOTS-c on day one, then emideltide (DSIP), Semax, and Epitalon on day two. A favorable recommendation on even one of these would open a legal compounding path for compounds that today move almost entirely through the gray market. The tension runs right through the panel: the FDA’s own career reviewers have already gone on record recommending against all seven, while the political appointees who convened the meeting are pushing the other way. Read the meeting notice and docket on the FDA’s site.

A few other things I flagged this week:

Tirzepatide edged semaglutide in a vessel-injury model. A study published July 11 in Biomedicines pitted both drugs against wire-injury arterial remodeling in mice and gave the dual-receptor agonist the advantage on the vascular side. Early and preclinical, but it adds to the case that the two drugs diverge well beyond the weight-loss numbers.

A new aging review maps the evidence gap. A Frontiers in Aging paper walks through nine longevity peptides, among them Epitalon, GHK-Cu, BPC-157, TB-500, and Semax. Five of those sit on the FDA’s July docket, and the review lays out plainly how thin the human data still is on the compounds about to get a vote.

The GLP-1 compounding door keeps closing. On a separate track from the research-peptide vote, the FDA is moving to keep the big GLP-1 (glucagon-like peptide-1) drugs, semaglutide, tirzepatide, and liraglutide, off the 503B bulks list and has sent another wave of warning letters to telehealth compounders over their marketing. Put the two tracks side by side and the direction is clear: tighter sourcing across the whole category.

Whichever way the vote lands, these compounds stay gray-market buys for now, and quality swings hard from one seller to the next. If you would rather vet a vendor than gamble, PeptidesRated compares them on lab testing and reputation.

Two weeks out, the realistic read is a split decision: maybe one or two of the seven clear the panel, the rest deferred, and any real rulemaking stretching well into 2027. I will have the votes broken down the Sunday after.

Austin